<DOC>
	<DOCNO>NCT02599259</DOCNO>
	<brief_summary>AiCure use artificial intelligence visual recognition technology confirm medication ingestion . The software available app download onto smart phone . The single-site , parallel-arm , randomize control trial test feasibility impact use platform stroke population . End point : usability , consistent use device , optimization treatment .</brief_summary>
	<brief_title>Using Artificial Intelligence Measure Optimize Adherence Patients Anticoagulation Therapy .</brief_title>
	<detailed_description>This study employ single-site , parallel-arm , randomized trial design . A total 50-100 human subjects- diagnosis ischemic stroke take one follow oral anticoagulant medication- Coumadin® ( warfarin ) , Pradaxa® ( dabigatran ) , Xarelto® ( rivaroxaban ) Eliquis® ( apixaban ) recruit study . All participant receive doctor 's treatment-as-usual . 1:1 randomization do baseline , +arm medication adherence monitor mean AiCure platform , participant assign control arm study . Study visit include screen visit , one two baseline visit ( ideally occur 7 14 day screen visit ) , monthly visit 12 week follow last baseline visit . Randomization occur final baseline visit . During final baseline visit , patient assign AiCure intervention arm provide training AiCure platform . While clinic , participant practice use AiCure app go detailed tutorial consist number interactive training step . Participants use substitute placebo practice medication order complete training tutorial . Study participant reimburse cover time transportation cost accordance Institutional Review Board ( IRB ) guideline . For length study , participant assign AiCure intervention arm study request take dose prescribed medication regimen use AiCure app . Data dose event save onto participant 's device encrypt data ( include de-identified video time date administration ) automatically transmit centralized dashboard . If study participant take dose use AiCure app ( self-reports confirm administration phone Study Coordinator manually self-reports AiCure App without go necessary step ) , miss dose ( participant fails take dose prior 'time next dose ' message appear device ) , use AiCure app incorrectly ( usability error suspicious behavior ) , Study Coordinator and/or AiCure team intervene detailed escalation protocol . Real-time adherence data automatically transmit cloud-based centralized dashboard intervention group . All subject INR DRVVT measure month ( frequently warfarin ) monitor medication adherence use point care device and/or laboratory monitoring ( upon Principal Investigator hematologist 's discretion ) clinic visit . All participant get prescription refill monthly visit . In addition , pill count do participant . If adherence sub-optimal base pill count , study coordinator document participant 's self-reported reason sub-optimal adherence . In addition , participant intervention group AiCure adherence rate review assess research staff , reason provide subject sub-optimal adherence record .</detailed_description>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Is male female least 18 year age . Having diagnosis ischemic stroke . Has score 1 20 NIH Stroke Survey ( NIHSS ) admission upon enrollment discharge index admission hospital first encounter outpatient stroke center . Is take one monitor drug Coumadin® , Pradaxa® , Xarelto® Eliquis® . Is go home acute outpatient rehabilitation discharge . Has sufficient capacity provide consent agree assent . Has least minimal mental capacity motor skill . Has poor fine motor skill , preclude him/her hold pill steady front camera . Has impair visual auditory faculty . Is release nursing home , hospice inpatient care facility . Has stable , therapeutic INRs warfarin least one year . Has mechanical mitral valve leave ventricular assist device .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Stroke</keyword>
	<keyword>Oral anticoagulant</keyword>
	<keyword>NOAC</keyword>
	<keyword>wireless monitoring</keyword>
	<keyword>Warfarin</keyword>
	<keyword>Xarelto</keyword>
	<keyword>compliance</keyword>
	<keyword>adherence</keyword>
	<keyword>monitoring</keyword>
	<keyword>directly observe therapy</keyword>
	<keyword>DOT</keyword>
	<keyword>mobile device</keyword>
	<keyword>electronic monitoring</keyword>
	<keyword>artificial intelligence</keyword>
	<keyword>oral anticoagulation therapy</keyword>
	<keyword>adherence monitoring method</keyword>
	<keyword>nonadherence</keyword>
	<keyword>non-adherence</keyword>
</DOC>